Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Lumicitabine
Другие языки:

Lumicitabine

Подписчиков: 0, рейтинг: 0
Lumicitabine
Lumicitabine structure.png
Clinical data
Trade names Lumicitabine
Legal status
Legal status
Identifiers
  • [(2R,3R,4R,5R)-5-(4-amino-2-oxopyrimidin-1-yl)-2-(chloromethyl)-4-fluoro-3-(2-methylpropanoyloxy)oxolan-2-yl]methyl 2-methylpropanoate
CAS Number
PubChem CID
ChemSpider
UNII
ECHA InfoCard 100.245.433
Chemical and physical data
Formula C18H25ClFN3O6
Molar mass 433.9 g·mol−1
3D model (JSmol)
  • CC(C)C(=O)OC[C@@]1([C@H]([C@H]([C@@H](O1)N2C=CC(=NC2=O)N)F)OC(=O)C(C)C)CCl
  • InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
  • Key:MJVKYGMNSQJLIN-KYZVSKTDSA-N

Lumicitabine (ALS-8176) is an antiviral drug which was developed as a treatment for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV). It acts as an RNA polymerase inhibitor. While it showed promise in early clinical trials, poor results in Phase IIb trials led to it being discontinued from development for treatment of RSV. Research continues to determine whether it may be useful for the treatment of diseases caused by other RNA viruses, and it has been found to show activity against Nipah virus.

See also


Новое сообщение